Compassionate use of remdesivir for patients with severe Covid-19: New England Journal of Medicine

J. Grein, N. Ohmagari, D. Shin, G. Diaz, E. Asperges, A. Castagna, T. Feldt, G. Green, M.L. Green, F.-X. Lescure, E. Nicastri, R. Oda, K. Yo, E. Quiros-Roldan, A. Studemeister, J. Redinski, S. Ahmed, J. Bernett, D. Chelliah, D. ChenS. Chihara, S.H. Cohen, J. Cunningham, A. D’Arminio Monforte, S. Ismail, H. Kato, G. Lapadula, E. L’Her, T. Maeno, S. Majumder, M. Massari, M. Mora-Rillo, Y. Mutoh, D. Nguyen, E. Verweij, A. Zoufaly, A.O. Osinusi, A. DeZure, Y. Zhao, L. Zhong, A. Chokkalingam, E. Elboudwarej, L. Telep, L. Timbs, I. Henne, S. Sellers, H. Cao, S.K. Tan, L. Winterbourne, P. Desai, R. Mera, A. Gaggar, R.P. Myers, D.M. Brainard, R. Childs, T. Flanigan

Research output: Contribution to journalArticlepeer-review


BACKGROUND Remdesivir, a nucleotide analogue prodrug that inhibits viral RNA polymerases, has shown in vitro activity against SARS-CoV-2. METHODS We provided remdesivir on a compassionate-use basis to patients hospitalized with Covid-19, the illness caused by infection with SARS-CoV-2. Patients were those with confirmed SARS-CoV-2 infection who had an oxygen saturation of 94% or less while they were breathing ambient air or who were receiving oxygen support. Patients received a 10-day course of remdesivir, consisting of 200 mg administered intravenously on day 1, followed by 100 mg daily for the remaining 9 days of treatment. This report is based on data from patients who received remdesivir during the period from January 25, 2020, through March 7, 2020, and have clinical data for at least 1 subsequent day. RESULTS Of the 61 patients who received at least one dose of remdesivir, data from 8 could not be analyzed (including 7 patients with no post-treatment data and 1 with a dosing error). Of the 53 patients whose data were analyzed, 22 were in the United States, 22 in Europe or Canada, and 9 in Japan. At baseline, 30 patients (57%) were receiving mechanical ventilation and 4 (8%) were receiving extracorporeal membrane oxygenation. During a median follow-up of 18 days, 36 patients (68%) had an improvement in oxygen-support class, including 17 of 30 patients (57%) receiving mechanical ventilation who were extubated. A total of 25 patients (47%) were discharged, and 7 patients (13%) died; mortality was 18% (6 of 34) among patients receiving invasive ventilation and 5% (1 of 19) among those not receiving invasive ventilation. CONCLUSIONS In this cohort of patients hospitalized for severe Covid-19 who were treated with compassionate-use remdesivir, clinical improvement was observed in 36 of 53 patients (68%). Measurement of efficacy will require ongoing randomized, placebo-controlled trials of remdesivir therapy. Copyright © 2020 Massachusetts Medical Society.
Original languageEnglish
Pages (from-to)2327-2336
Number of pages10
JournalNew Engl. J. Med.
Issue number24
Publication statusPublished - 2020


  • remdesivir
  • adenosine phosphate
  • alanine
  • antivirus agent
  • adult
  • ambient air
  • Article
  • artificial ventilation
  • breathing
  • compassionate use
  • coronavirus disease 2019
  • disease severity
  • drug use
  • extracorporeal oxygenation
  • extubation
  • female
  • follow up
  • human
  • major clinical study
  • male
  • mortality rate
  • oxygen saturation
  • priority journal
  • Severe acute respiratory syndrome coronavirus 2
  • aged
  • Betacoronavirus
  • Canada
  • Coronavirus infection
  • Europe
  • intravenous drug administration
  • Japan
  • middle aged
  • mortality
  • pandemic
  • United States
  • very elderly
  • virus pneumonia
  • young adult
  • Adenosine Monophosphate
  • Administration, Intravenous
  • Adult
  • Aged
  • Aged, 80 and over
  • Alanine
  • Antiviral Agents
  • Compassionate Use Trials
  • Coronavirus Infections
  • Female
  • Humans
  • Male
  • Middle Aged
  • Pandemics
  • Pneumonia, Viral
  • Respiration, Artificial
  • Young Adult


Dive into the research topics of 'Compassionate use of remdesivir for patients with severe Covid-19: New England Journal of Medicine'. Together they form a unique fingerprint.

Cite this